» Articles » PMID: 37894222

Differential Immune-Modulating Activities of Cell Walls and Secreted Metabolites from Probiotic JBI-YZ6.3 Under Normal Versus Inflamed Culture Conditions

Overview
Journal Microorganisms
Specialty Microbiology
Date 2023 Oct 28
PMID 37894222
Authors
Affiliations
Soon will be listed here.
Abstract

Spore-forming probiotic bacteria, including , are resilient and produce a variety of beneficial metabolites. We evaluated the immune-modulating effects of the novel probiotic strain JBI-YZ6.3, where the germinated spores, metabolite fraction, and cell wall fraction were tested in parallel using human peripheral blood mononuclear cell cultures under both normal and lipopolysaccharide-induced inflamed culture conditions. The expression of CD25 and CD69 activation markers was evaluated via flow cytometry. Supernatants were tested for cytokines, interferons, chemokines, and growth factors using Luminex arrays. The germinated spores were highly immunogenic; both the cell wall and metabolite fractions contributed significantly. Under normal culture conditions, increased levels of immune activation were observed as increased expressions of CD25 and CD69 relative to natural killer cells, suggesting an increased ability to attack virus-infected target cells. On monocytes, a complex effect was observed, where the expression of CD25 increased under normal conditions but decreased under inflamed conditions. This, in combination with increased interleukin-10 (IL-10) and decreased monocyte chemoattractant protein-1 (MCP-1) production under inflamed conditions, points to anti-inflammatory effects. The production of the stem cell-related growth factor granulocyte colony-stimulating Factor (G-CSF) was enhanced. Further research is warranted to characterize the composition of the postbiotic metabolite fraction and document the characteristics of immunomodulating agents secreted by this probiotic strain.

Citing Articles

Secreted Metabolites from , , and Biofilm: Modulation of Immunogenicity by a Nutraceutical Enzyme and Botanical Blend.

Cruickshank D, Hamilton D, Iloba I, Jensen G Microorganisms. 2024; 12(5).

PMID: 38792820 PMC: 11124038. DOI: 10.3390/microorganisms12050991.

References
1.
Aulitto M, Strazzulli A, Sansone F, Cozzolino F, Monti M, Moracci M . Prebiotic properties of Bacillus coagulans MA-13: production of galactoside hydrolyzing enzymes and characterization of the transglycosylation properties of a GH42 β-galactosidase. Microb Cell Fact. 2021; 20(1):71. PMC: 7977261. DOI: 10.1186/s12934-021-01553-y. View

2.
Le Marrec C, Hyronimus B, Bressollier P, Verneuil B, Urdaci M . Biochemical and genetic characterization of coagulin, a new antilisterial bacteriocin in the pediocin family of bacteriocins, produced by Bacillus coagulans I(4). Appl Environ Microbiol. 2000; 66(12):5213-20. PMC: 92446. DOI: 10.1128/AEM.66.12.5213-5220.2000. View

3.
Morrison D, Preston T . Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes. 2016; 7(3):189-200. PMC: 4939913. DOI: 10.1080/19490976.2015.1134082. View

4.
Upadrasta A, Pitta S, Madempudi R . Draft Genome Sequence of the Spore-Forming Probiotic Strain Bacillus coagulans Unique IS-2. Genome Announc. 2016; 4(2). PMC: 4841124. DOI: 10.1128/genomeA.00225-16. View

5.
Gomaa E . Human gut microbiota/microbiome in health and diseases: a review. Antonie Van Leeuwenhoek. 2020; 113(12):2019-2040. DOI: 10.1007/s10482-020-01474-7. View